AR007020A1 - TREATMENT OF ASTHMA WITH TNFR-IG - Google Patents

TREATMENT OF ASTHMA WITH TNFR-IG

Info

Publication number
AR007020A1
AR007020A1 ARP970101876A ARP970101876A AR007020A1 AR 007020 A1 AR007020 A1 AR 007020A1 AR P970101876 A ARP970101876 A AR P970101876A AR P970101876 A ARP970101876 A AR P970101876A AR 007020 A1 AR007020 A1 AR 007020A1
Authority
AR
Argentina
Prior art keywords
asthma
treatment
tnf
tnfr
alpha binding
Prior art date
Application number
ARP970101876A
Other languages
Spanish (es)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR007020A1 publication Critical patent/AR007020A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se refiere a un método para combatir el asma con una composición que contiene una cantidad eficaz de una proteína quimérica de unión a TNF-alfaque incluye la porción soluble del receptor de TNF p55 y todos los dominios excepto elprime r dominio de la región constante de la cadena pesada de la IgG1o IgG3 humanas, y al uso de dicha proteína quimérica de unión a TNF-alfa para la preparación de un medicamento para el tratamiento del asma.Refers to a method of fighting asthma with a composition containing an effective amount of a chimeric TNF-alpha binding protein that includes the soluble portion of the TNF receptor p55 and all domains except the first domain of the constant region of the heavy chain of human IgG1 or IgG3, and the use of said TNF-alpha binding chimeric protein for the preparation of a medicament for the treatment of asthma.

ARP970101876A 1996-05-08 1997-05-06 TREATMENT OF ASTHMA WITH TNFR-IG AR007020A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1684296P 1996-05-08 1996-05-08

Publications (1)

Publication Number Publication Date
AR007020A1 true AR007020A1 (en) 1999-10-13

Family

ID=21779275

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101876A AR007020A1 (en) 1996-05-08 1997-05-06 TREATMENT OF ASTHMA WITH TNFR-IG

Country Status (15)

Country Link
EP (1) EP0910413A2 (en)
JP (1) JP2000510113A (en)
KR (1) KR20000010825A (en)
CN (1) CN1233189A (en)
AR (1) AR007020A1 (en)
AU (1) AU725408B2 (en)
BR (1) BR9708928A (en)
CA (1) CA2253557A1 (en)
CO (1) CO4820397A1 (en)
HR (1) HRP970224A2 (en)
MA (1) MA24169A1 (en)
PE (1) PE70698A1 (en)
TR (1) TR199802238T2 (en)
WO (1) WO1997041895A2 (en)
ZA (1) ZA973843B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508934A (en) * 1997-12-29 2002-03-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Novel nucleic acids and polypeptides having homology to the TNF receptor
TR200504220T2 (en) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Active lymphotoxin-beta receptor immunoglobulin chime A method for high level expression and purification of purified protein proteins and a method for purification of active lymphotoxin-beta receptor immunoglobulin chimeric proteins.
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
RS51041B (en) * 2003-02-28 2010-10-31 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding protein tbp-1
US7335491B2 (en) * 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
SG154441A1 (en) 2006-10-20 2009-08-28 Biogen Idec Inc Treatment of demyelinating disorders
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0417563B1 (en) * 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag TNF-binding proteins
WO1994006476A1 (en) * 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5684222A (en) * 1993-01-22 1997-11-04 Ontario Cancer Institute Mutant mouse having a disrupted TNFRp55
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
EP0772449A1 (en) * 1994-07-22 1997-05-14 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising a chimaeric tnf binding protein
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND

Also Published As

Publication number Publication date
TR199802238T2 (en) 1999-02-22
CO4820397A1 (en) 1999-07-28
WO1997041895A2 (en) 1997-11-13
CA2253557A1 (en) 1997-11-13
AU2776497A (en) 1997-11-26
EP0910413A2 (en) 1999-04-28
HRP970224A2 (en) 1998-04-30
KR20000010825A (en) 2000-02-25
PE70698A1 (en) 1998-11-18
ZA973843B (en) 1997-11-10
WO1997041895A3 (en) 1998-03-12
JP2000510113A (en) 2000-08-08
BR9708928A (en) 2000-05-09
MA24169A1 (en) 1997-12-31
CN1233189A (en) 1999-10-27
AU725408B2 (en) 2000-10-12

Similar Documents

Publication Publication Date Title
TR200101481T2 (en) Cancer treatment composition and method using natural herbal essential oils.
UA49814C2 (en) Composition containing papilome virus antigen, cervical cancer curing method, acute condilome curing method
TR200100922T2 (en) Application of active substances through the lungs.
FI962154A (en) Composition for the in vivo preparation of therapeutic products
UA52594C2 (en) Cycloalcanopyridine derivatives, mixture of isomers thereof or individual isomers, their salts and n-oxides, methods and intermediate compounds for preparation thereof, a also a pharmaceutical composition
IL134888A0 (en) HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING THEM AND THERAPEUTIC USE THEREOF
WO1999058674A3 (en) Method of inhibiting osteoclast activity
PL329802A1 (en) Derivatives of androstene
EE9700225A (en) A method of treating diabetes mellitus using KKF
UA37259C2 (en) Active substance for pharmaceutical compositions intended for treatment of dysfunctional metrorrhagia
ES2185660T3 (en) NEW USE OF DEXMEDETOMIDINE.
ES2190205T3 (en) COMBINATION FOR THE TREATMENT OF THE ALCOHOL DEPENDENCE CONTAINING AN OPIOID ANTAGONIST AND A NMDA RECEPTOR COMPLEX MODULATOR.
IT8419308A0 (en) PROCEDURE FOR THE PREPARATION OF GALENIC FORMULATIONS PARTICULARLY FOR PHARMACEUTICAL, DIETARY, COSMETIC AND DIAGNOSTIC USE.
EE04046B1 (en) Pharmaceutical composition containing vitamin D and calcium, its preparation and therapeutic use
AR007020A1 (en) TREATMENT OF ASTHMA WITH TNFR-IG
ES2174054T3 (en) PHARMACEUTICAL LIQUID PHARMACEUTICAL COMPOSITIONS INCLUDING SODIUM ALGINATE AND POTASSIC BICARBONATE.
AR007165A1 (en) PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING DICLOFENAC.
ECSP972104A (en) TREATMENT OF ASTHMA WITH TNFR - IG
IL129536A0 (en) Therapeutic and cosmetic compositions their use and method for the preparation thereof
ES2175661T3 (en) DERIVATIVES OF ISOFLAVONA, PROCEDURES FOR THE PREPARATION OF THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DK0722325T3 (en) Preparation for the treatment or prevention of herpes
ES2163001T3 (en) NEW DERIVATIVES OF BORNEOL, PROCEDURE FOR ITS PREPARATION AND ITS PHARMACEUTICAL USE.
ATE107164T1 (en) USE OF THROMBOXAN-A2 ANTAGONISTS TO PREVENT DEGENERATIVE PROCESSES IN PENILE TISSUE.
JPS56128705A (en) Acaricidal composition
GB9211277D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
FA Abandonment or withdrawal